Request Legal Help Now - Free


J&J Agrees to Pay $85 Million for Natrecor Misbranding

This is a settlement for the Whistleblower lawsuit.

Washington, DC: Johnson & Johnson subsidiary, Scios, has agreed to pay $85 million to settle a criminal misdemeanour charge of misbranding its drug Natrecor, used to treat heart failure.

The charges stemmed from a Justice Department probe into allegations brought by a whistleblower that Scios was promoting Natrecor for off-label use as a routine, outpatient infusion, when it is only FDA approved for use to treat congestive heart failure patients in hospitals and emergency rooms. The settlement doesn't exempt Scios or J&J from separate civil claims in a pending False Claims Act suit.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on Oct-11-11


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free